University Hospitals Coventry and Warwickshire (UHCW) NHS Trust is to lead a clinical trial of a novel device aimed at addressing miscarriage symptoms.
Rachel Thrasher, Research Fellow at the Global Development Policy Center in Boston, explains how the TRIPS COVID-19 waiver rejected by the WTO could ramp up global vaccine production.
Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable childhood cancer that has no effective treatment - but now, scientists in Australia believe they have found a drug that could begin to treat this cancer.
UK based scientists witnessed how COVID-19 can mutate in a highly vulnerable patient, even when that person is undergoing convalescent plasma treatment.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
AstraZeneca CEO Pascal Soriot spoke to Antonello Guerrera about the ongoing vaccine feud - with the Commission receiving 60% less than expected, raising tense questions about why.
EU leaders are investigating why AstraZeneca are not following through with the pre-agreed number of vaccines for the Member States - taking a 60% cut to the expected amount.
The São Paulo Government and Butantan Institute revealed that the Sinovac COVID-19 vaccine is 15.6% less effective than officials previously suggested.
The projects will happen in 14 Member States and the United Kingdom, with 36 million in funding to get COVID-19 plasma to patients - boosting their immune response to the virus.
The independent experts of the FDA say the Pfizer vaccine is good to go, which means that the COVID vaccine should be formally approved in a matter of days.
In this interview, Prof Christophe Drouet (CNRS Senior Scientist) – an international specialist in bio-inspired apatites – relates the multifunctional potential of these intrinsically biocompatible compounds for a wealth of uses from bone tissue repair, to cell-scale medicine.
Teva and Cephalon faced the €60.5 million antitrust fine, after both companies were found to be actively suppressing the existence of cheaper medicine.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
